Fig. 1: Establishment of a longitudinal GL261 GB murine model. | Nature Communications

Fig. 1: Establishment of a longitudinal GL261 GB murine model.

From: Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma

Fig. 1

a Overview of the in vivo study design enabling plasma and brain tissue proteomic profiling in GB tumour-bearing mice. A syngeneic GB murine model was established in C57BL/6 J female mice via intracranial injection of GL261 cells. Control mice underwent sham injection with saline. PEGylated liposome nanoparticles (NPs) were intravenously administered at days 7, 14, and 18 post-intracranial GL261 cell injection to allow protein corona formation. The corona-coated NPs were subsequently recovered from the blood circulation and purified to remove any unbound proteins. Brains were collected from control and tumour-bearing mice at all three-time points of investigation. Created in BioRender. Hadjidemetriou, M. (2025) https://BioRender.com/z49a544. b Histological characterisation of GL261 tumours at day 7 (D7), day 14 (D14), and day 18 (D18) by haematoxylin and eosin (H&E) staining. c Quantification of the tumour volume in GB mice at days 7, 14, and 18 (n = 9 biological replicates for D7 and D14, n = 8 biological replicates for D18; error bars indicate mean ± SEM; *p-value = 0.0409 between D7 and D14, ****p-value < 0.0001 between D7 and D18, ****p-value < 0.0001 between D14 and D18 by One-way ANOVA with Tukey’s multiple comparison test). Source data for Fig. 1c are provided as a Source Data file.

Back to article page